Withdrawal of insulin therapy after adjunctive treatment with acarbose in a patient with Type 2 diabetes mellitus
โ Scribed by Bennett, SMA ;Stewart, MW
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 269 KB
- Volume
- 15
- Category
- Article
- ISSN
- 1357-8170
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Acarbose has been shown to reduce postโprandial hyperglycaemia and improve glycaemic control in patients with Type 2 diabetes mellitus. We report its use as an adjunct to established insulin therapy in a 64 year old man with Type 2 diabetes mellitus and secondary failure to treatment with a sulphonylurea. Following the addition of acarbose to his treatment regimen his insulin therapy was completely withdrawn. Associated with this was a documented weight loss of 7kg and reduction in glycated haemoglobin of 2.7%. Acarbose can be of potential benefit in the management of poorly controlled Type 2 diabetes.
๐ SIMILAR VOLUMES
Background Both HMG-CoA reductase inhibitors and ยฎbric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg bezaยฎbrate, a ยฎbric acid deriva
We evaluated the effect of insulin on platelet function, blood viscosity, and filterability in healthy subjects and in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Fifteen diabetic patients were free from cardiovascular complications (group A), while the other 15 patients had both
Type 2 (non-insulin dependent) diabetes mellitus may be inherited along the maternal line and a variety of mitochondrial DNA (mtDNA) variants have been implicated in the pathogenesis. We have previously reported mutations in five regions of the mitochondrial genome which encompass 11 of the 22 tRNA